Eurofins debuts combined tests for COVID-19, flu, RSV

LabPulse.com staff writers
Nov 17, 2020
2020 06 29 16 41 7549 Pathogenic Bacteria Viruses 400

Eurofins Viracor has launched several combined tests that detect SARS-CoV-2 infection, as well as influenza A and B and respiratory syncytial virus (RSV).

The combined SARS-CoV-2 plus flu A/B and RSV tests aim for the qualitative detection of SARS-CoV-2 and the quantitative detection of influenza A, influenza B, and RSV. The combined COVID-19 and flu test now can be ordered as individual tests.

The combined COVID-19, flu, and RSV test is expected to launch on December 7.

Latest in Influenza
Fda Button Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
March 20, 2023
Flu Season Ahead Social
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
December 8, 2022
Flu Season Ahead Social
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
November 21, 2022
Respiratory Syncytial Virus Cdc Social
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
November 3, 2022
Related Stories
Fda Button Social
Emergency Use Authorization
Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings
Covid Test Preschool Social
COVID-19
Sameday Health launches swab test in Los Angeles for COVID-19, flu, RSV
Women Laboratory Social
Trends and Finance
Eurofins Viracor opens lab to support growth in biopharma, transplant diagnostic testing
2021 01 11 17 03 4617 Covid Diagnostic Test Kit 400
Molecular Diagnostics
Eurofins lands $30M COVID diagnostic testing contract
More in Influenza
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
Two mutations in the matrix genes of the human influenza A virus have been reported to cause matrix gene target failure for several commercial diagnostic tests.
December 8, 2022
Flu Season Ahead Social
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
The hemagglutinin and neuraminidase antigens were developed in response to flu vaccine formulations the World Health Organization selected for development in the Southern Hemisphere.
November 21, 2022
Flu Season Ahead Social
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
Respiratory Syncytial Virus Cdc Social
University of Illinois spinout Shield T3 launches saliva-based PCR test for COVID, flu, RSV
Shield T3, a spinout of the University of Illinois, will offer a triple-virus PCR test kit, in anticipation of increased cases of COVID-19, flu, and RSV this winter.
October 25, 2022
Covid Diagnostic Test Kit
Walgreens Flu Index shows 2022-2023 season exhibiting tenfold increase over last year
The Walgreens Flu Index indicates that flu activity this year is more than 10 times higher than in the previous year and has doubled over the past two weeks.
October 24, 2022
Influenza Virus Cdc
Most Popular
Quest launches long-COVID testing panels for consumers
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
More in Influenza
DiaSorin developing point-of-care molecular test for SARS-CoV-2, influenza under BARDA contract
DiaSorin will develop, verify, and clinically validate a point-of-care instrument and an initial combination test for SARS-CoV-2 and influenza A and B.
October 7, 2022
Influenza Virus
Siemens releases tests for seasonal respiratory pathogens
The CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV PCR assay is available to laboratories, while the Clinitest Rapid COVID-19 + Influenza Antigen Test is used at the point of care.
September 14, 2022
2022 02 04 20 07 5010 Siemens Rsna 2021 400
MagBio Genomics secures 510(k), CE Mark approval
A guanidine-free molecular transport medium, the MagXtract Collection Tube eliminates the risk of accidentally creating cyanide gas during cleaning, directly lyses cells during transport, inactivates pathogens, and maintains ambient temperature stability of RNA samples for up to eight days, thus eliminating the need for cold storage and shipping, the firm said.
September 11, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Cue Health requests FDA de novo clearance for at-home flu test
Clearance would permit the test to be used at home and elsewhere at the point-of-care (POC).
September 1, 2022
2022 09 02 19 52 9683 Flu Season Ahead 400
Hologic launches respiratory assays in Europe
Both products are compliant with the European In Vitro Diagnostic Medical Device Directive (IVDD) and are being made available in time for the Northern Hemisphere's respiratory viral season, the firm said.
July 10, 2022
2022 04 29 18 14 4601 Hologic Rsna 2019 400
BD nabs CE Mark for respiratory viral panel
The panel, a molecular diagnostic combination test for SARS-CoV-2, influenza A + B, and respiratory syncytial virus (RSV), uses a nasal swab or nasopharyngeal swab sample.
June 30, 2022
2019 05 02 23 38 2538 Check Mark 400
Page 1 of 6
Next Page